Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation.

Citation metadata

Publisher: BioMed Central Ltd.
Document Type: Article
Length: 9,547 words
Lexile Measure: 1500L

Document controls

Main content

Abstract :

Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers. Exploring the mechanism of Bcl-x splicing and regulation has provided insight into the development of drugs that could contribute to sensitivity of cancer cells to death. On this basis, we review the multiple splicing patterns and structural characteristics of Bcl-x. Additionally, we outline the cis-regulatory elements, trans-acting factors as well as epigenetic modifications involved in the splicing regulation of Bcl-x. Furthermore, this review highlights aberrant splicing of Bcl-x involved in apoptosis evade, autophagy, metastasis, and therapy resistance of various cancer cells. Last, emphasis is given to the clinical role of targeting Bcl-x splicing correction in human cancer based on the splice-switching oligonucleotides, small molecular modulators and BH3 mimetics. Thus, it is highlighting significance of aberrant splicing isoforms of Bcl-x as targets for cancer therapy. Keywords: Bcl-x, Alternative splicing, Cell apoptosis, Splicing correction, Splice-switching oligonucleotides, Small molecular modulators

Source Citation

Source Citation   

Gale Document Number: GALE|A665426213